martes, 5 de julio de 2016

National Guideline Clearinghouse | TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis.

National Guideline Clearinghouse | TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis.

National Guideline Clearinghouse (NGC)

National Institute for Health and Care Excellence (NICE)


Guideline Title
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Bibliographic Source(s)
National Institute for Health and Care Excellence (NICE). TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis. London (UK): National Institute for Health and Care Excellence (NICE); 2016 Feb 1. 70 p. (Technology appraisal guidance; no. 383). 
Guideline Status
This is the current release of the guideline.
This guideline updates a previous version: National Institute for Health and Clinical Excellence (NICE). Adalimumab, etanercept and infliximab for ankylosing spondylitis. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 May. 47 p. (Technology appraisal guidance; no. 143).
This guideline meets NGC's 2013 (revised) inclusion criteria.

No hay comentarios:

Publicar un comentario